Evidence item

The primary AMP-trial analysis reports VRC01-associated escape in treated participants, low global frequencies, cross-resistance for some antibodies, and retained activity for N6 and 1–18. DIRECT_TEXT

Authenticity UNVERIFIED · extraction UNVERIFIED · independence group none (unreviewed) · created seq 20142

Source: Prophylactic treatment with broadly neutralizing antibody VRC01 selects for escape mutants after infection in Antibody-Mediated Prevention trials · locator {} · excerpt hash sha256:8edade27d7475d51cd044c236539ee519a7254d28e2cedb4b37c93665096eed9

Exact excerpt

Here we analysed 11,730 HIV envelope sequences generated during the AMP trials from 47 participants, identifying VRC01-mediated de novo escape mutations in 8 of 26 VRC01-treated participants but none in 21 placebo participants. These mutations were found at very low frequencies (<1%) in globally circulating viruses, suggesting that they may confer fitness costs. Escape mutations, primarily located in the Loop-D and β23/V5 regions of Env, conferred cross-resistance to several CD4bs bnAbs; however, more potent CD4bs bnAbs such as N6 and 1–18 largely retained their activity.

Linked claims

Claim	Direction	Relevance	Steps	Counted
fc4c6343	SUPPORT	DIRECT	0	yes

Audits

None.